Meeder Asset Management Inc Seres Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$6.02 - $11.43 $8,446 - $16,036	-1,403 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$5.46 - $22.6 $7,660 - $31,707	1,403 New	1,403 $9,000
Q2 2021 Aug 09, 2021	SELL	$18.46 - $24.36 $23,776 - $31,375	-1,288 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$17.66 - $28.92 $22,746 - $37,248	1,288 New	1,288 $26,000
Q4 2020 Feb 09, 2021	SELL	$23.25 - $37.73 $61,403 - $99,644	-2,641 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$3.74 - $28.74 $6,844 - $52,594	1,830 Added 225.65%	2,641 $74,000
Q2 2020 Aug 11, 2020	BUY	$3.04 - $6.2 $212 - $434	70 Added 9.45%	811 $3,000
Q1 2020 May 15, 2020	BUY	$2.64 - $3.82 $1,956 - $2,830	741 New	741 $3,000
Q2 2019 Aug 05, 2019	SELL	$2.28 - $7.35 $1,593 - $5,137	-699 Closed	0 $0
Q1 2019 Apr 16, 2019	BUY	$4.83 - $7.21 $3,376 - $5,039	699 New	699 $5,000
Q4 2017 Feb 02, 2018	SELL	$9.15 - $12.64 $448 - $619	-49 Closed	0 $0
Q3 2017 Oct 20, 2017	BUY	$12.81 - $16.85 $627 - $825	49	49 $1,000

46.3M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $118M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.